NCT05518188View on ClinicalTrials.gov

Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

October 1, 2028

Study Completion Date

October 1, 2030

Conditions
Spasticity, MuscleMicrocephalyIntellectual DeficiencyGrowth RetardationSPG50Spastic Paraplegia
Interventions
BIOLOGICAL

MELPIDA

MELPIDA, a recombinant serotype 9 adeno-associated virus (AAV) encoding a codon-optimized human AP4M1 transgene

Trial Locations (1)

75235

RECRUITING

Children's Medical Center Dallas, Dallas

Sponsors
All Listed Sponsors
collaborator

University of Texas Southwestern Medical Center

OTHER

lead

Elpida Therapeutics SPC

INDUSTRY